A carregar...

DUB3 promotes BET inhibitor resistance and cancer progression through deubiquitinating BRD4

The bromodomain and extra-terminal domain (BET) protein BRD4 is emerging as a promising anticancer therapeutic target. However, resistance to BET inhibitors often occurs and it has been linked to aberrant degradation of BRD4 protein in cancer. Here, we demonstrate that the deubiquitinase DUB3 binds...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Mol Cell
Main Authors: Jin, Xin, Yan, Yuqian, Wang, Dejie, Ding, Donglin, Ma, Tao, Ye, Zhenqing, Jimenez, Rafael, Wang, Liguo, Wu, Heshui, Huang, Haojie
Formato: Artigo
Idioma:Inglês
Publicado em: 2018
Assuntos:
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC6086352/
https://ncbi.nlm.nih.gov/pubmed/30057199
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.molcel.2018.06.036
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!